State of the Art Infrastructure with DSIR recognized R&D Lab
Aegis is in mode of continual improvement and expansion of manufacturing facility to take care of market need for next generation of medical devices.
With full-fledged state of art R&D infrastructure, Equipment and Manpower including collaboration activities with reputes Scientific and health care institutions in India and abroad, The R&D is well equipped to meet the requirements from Design, IPR, In-vitro testing, Design transfer meeting the highest standard of Regulatory requirements (ISO 13485: 2016 / Clause 7.2) / MRD, USFDA 510K and 21 CFR).
Aegis has been approved the DSIR accreditation (F.No. TU/ IV – RD/4698/2021) for its R&D Facility for the activities that had been undertaken in the past and for projects in future.
Objectives of the R&D Program
Customer-driven R&D is Aegis lifeline into the future, and the Aegis plant features a full-fledged R&D, with best-in-class facilities and an experienced pool of techno-professionals.
The focus of R&D here is both product-centric and customer-centric, and an all-out effort is made to meet, satisfy and exceed the customers’ existent and emergent needs and requirements.
Aegis’s R&D team, thanks to their frontline expertise, has a comprehensive understanding of the entire process & products. Thus, offer customers optimal product solutions – optimizing the total usage cost of Aegis’s products at their end.
Balancing business goals, technology objectives, and user needs attainability are three key ingredients is and finding the right mix for the company in relationship to each individual device.
The R&D projects will enable the company ample scope to enter the third-generation haemostats and sealants. It also enables the company to expand to other product portfolios and verticals in the same or other segments and benchmark as technology based company.
Comments
Post a Comment